{"title":"Correlation of PET/CT Maximal Standardized Uptake Values with Clinicopathologic Parameters of Aggressive Non-Hodgkin's Lymphoma.","authors":"Yingci Li, Dongbo Wu, Mohan Tian","doi":"10.2147/CMAR.S522628","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To investigate the correlation between the maximum standardized uptake value (SUV<sub>max</sub>) of positron emission tomography (PET)/computed tomography (CT) scanning imaging with the clinicopathologic parameters of aggressive non-Hodgkin's lymphoma (NHL) and its diagnostic value.</p><p><strong>Methods: </strong>A total of 128 patients with NHL were retrospectively selected. PET/CT examination was performed to calculate SUV<sub>max</sub>, and clinicopathological data were collected. Pearson correlation test was used to analyze the correlation between them, and the relevant indicators were detected according to the pathological results. ROC curve was used to analyze the diagnostic value.</p><p><strong>Results: </strong>The level of PET/CT SUV<sub>max</sub> was positively correlated with the levels of β2-microglobulin (β2-MG), lactate dehydrogenase (LDH), Ki-67, tumor size and bone marrow infiltration (P<0.05). The PET/CT SUV<sub>max</sub> and serum β2-MG, LDH and Ki-67 levels in the aggressive group were significantly higher than those in the indolent group (P<0.05). The AUC of the combined detection of PET/CT SUV<sub>max</sub>, β2-MG, LDH and Ki-67 in the diagnosis of aggressive NHL was 0.920, and the combined detection had a high diagnostic value.</p><p><strong>Conclusion: </strong>PET/CT SUV<sub>max</sub> was correlated with a variety of clinicopathological parameters. Combined detection of PET/CT SUV<sub>max</sub> has high diagnostic value in aggressive NHL.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"975-984"},"PeriodicalIF":2.5000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106917/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Management and Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/CMAR.S522628","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To investigate the correlation between the maximum standardized uptake value (SUVmax) of positron emission tomography (PET)/computed tomography (CT) scanning imaging with the clinicopathologic parameters of aggressive non-Hodgkin's lymphoma (NHL) and its diagnostic value.
Methods: A total of 128 patients with NHL were retrospectively selected. PET/CT examination was performed to calculate SUVmax, and clinicopathological data were collected. Pearson correlation test was used to analyze the correlation between them, and the relevant indicators were detected according to the pathological results. ROC curve was used to analyze the diagnostic value.
Results: The level of PET/CT SUVmax was positively correlated with the levels of β2-microglobulin (β2-MG), lactate dehydrogenase (LDH), Ki-67, tumor size and bone marrow infiltration (P<0.05). The PET/CT SUVmax and serum β2-MG, LDH and Ki-67 levels in the aggressive group were significantly higher than those in the indolent group (P<0.05). The AUC of the combined detection of PET/CT SUVmax, β2-MG, LDH and Ki-67 in the diagnosis of aggressive NHL was 0.920, and the combined detection had a high diagnostic value.
Conclusion: PET/CT SUVmax was correlated with a variety of clinicopathological parameters. Combined detection of PET/CT SUVmax has high diagnostic value in aggressive NHL.
期刊介绍:
Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients. Specific topics covered in the journal include:
◦Epidemiology, detection and screening
◦Cellular research and biomarkers
◦Identification of biotargets and agents with novel mechanisms of action
◦Optimal clinical use of existing anticancer agents, including combination therapies
◦Radiation and surgery
◦Palliative care
◦Patient adherence, quality of life, satisfaction
The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews & evaluations, guidelines, expert opinion and commentary, and case series that shed novel insights on a disease or disease subtype.